Amino Acid Restriction Triggers Angiogenesis via GCN2/ATF4 Regulation of VEGF and H2S Production by Longchamp, Alban et al.
Article
Amino Acid Restriction Triggers Angiogenesis via
GCN2/ATF4 Regulation of VEGF and H2S ProductionGraphical AbstractHighlightsd Sulfur amino acid (SAA) restriction triggers angiogenesis
independent of hypoxia or HIF1a
d GCN2/ATF4 pathway regulates VEGF and CGL expression
upon SAA restriction in ECs
d CGL is required for skeletal muscle angiogenesis activated
by diet or exercise
d H2S triggers glucose uptake, glycolysis, and PPP
concomitant with OXPHOS inhibition in ECsLongchamp et al., 2018, Cell 173, 117–129
March 22, 2018 ª 2018 Elsevier Inc.
https://doi.org/10.1016/j.cell.2018.03.001Authors
Alban Longchamp, Teodelinda Mirabella,
Alessandro Arduini, ...,
Christopher S. Chen, C. Keith Ozaki,
James R. Mitchell
Correspondence
jmitchel@hsph.harvard.edu
In Brief
Restricting dietary sulfur amino acids can
trigger angiogenesis and improve
vascular health.
ArticleAmino Acid Restriction Triggers
Angiogenesis via GCN2/ATF4 Regulation
of VEGF and H2S Production
Alban Longchamp,1,2,10 Teodelinda Mirabella,3,4,10 Alessandro Arduini,1,10 Michael R. MacArthur,1 Abhirup Das,5,6
J. Humberto Trevin˜o-Villarreal,1 Christopher Hine,1 Issam Ben-Sahra,1 Nelson H. Knudsen,1 Lear E. Brace,1
Justin Reynolds,1 Pedro Mejia,1 Ming Tao,2 Gaurav Sharma,2 Rui Wang,7 Jean-Marc Corpataux,8
Jacques-Antoine Haefliger,8 Kyo Han Ahn,9 Chih-Hao Lee,1 Brendan D. Manning,1 David A. Sinclair,5,6
Christopher S. Chen,3,4 C. Keith Ozaki,2 and James R. Mitchell1,11,*
1Department of Genetics and Complex Diseases, Harvard T.H. Chan School of Public Health, Boston, MA, USA
2Department of Surgery and the Heart and Vascular Center, Brigham & Women’s Hospital and Harvard Medical School, Boston, MA, USA
3Tissue Microfabrication Lab, Department of Biomedical Engineering, Boston University, Boston, MA, USA
4Wyss Institute for Biologically Inspired Engineering, Boston, MA, USA
5Glenn Center for the Biological Mechanisms of Aging, Department of Genetics, Harvard Medical School, Boston, MA 02115, USA
6Laboratory for Ageing Research, Department of Pharmacology, School of Medical Sciences, University of New South Wales,
Sydney NSW 2052, Australia
7Cardiovascular and Metabolic Research Unit, Laurentian University, Sudbury, ON, Canada
8Department of Vascular Surgery, Laboratory of Experimental Medicine, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
9Department of Chemistry, Postech, 77 Cheongam-Ro, Nam-Gu, Pohang, 37673, Republic of Korea
10These authors contributed equally
11Lead Contact
*Correspondence: jmitchel@hsph.harvard.edu
https://doi.org/10.1016/j.cell.2018.03.001SUMMARY
Angiogenesis, the formation of new blood vessels by
endothelial cells (ECs), is an adaptive response to ox-
ygen/nutrient deprivation orchestrated by vascular
endothelial growth factor (VEGF) upon ischemia or
exercise. Hypoxia is the best-understood trigger of
VEGF expression via the transcription factor HIF1a.
Nutrient deprivation is inseparable from hypoxia dur-
ing ischemia, yet its role in angiogenesis is poorly
characterized. Here, we identified sulfur amino acid
restriction as a proangiogenic trigger, promoting
increased VEGF expression, migration and sprouting
in ECs in vitro, and increased capillary density in
mouse skeletal muscle in vivo via the GCN2/ATF4
amino acid starvation response pathway indepen-
dent of hypoxia or HIF1a. We also identified a
requirement for cystathionine-g-lyase in VEGF-
dependent angiogenesis via increased hydrogen
sulfide (H2S) production. H2S mediated its proangio-
genic effects in part by inhibiting mitochondrial
electron transport and oxidative phosphorylation, re-
sulting in increased glucose uptake and glycolytic
ATP production.
INTRODUCTION
Angiogenesis is the formation of new blood vessels from existing
ones through sprouting, proliferation, and migration of endothe-lial cells (ECs). In adult mammals, angiogenesis is an adaptive
response to normal and pathophysiological conditions charac-
terized by inadequate supply of oxygen and nutrients, ranging
from tissue ischemia upon vessel occlusion or tumorigenesis
to endurance exercise.
Hypoxia is the best-understood trigger of angiogenesis, stabi-
lizing the oxygen-sensitive transcription factor hypoxia-inducible
factor (HIF)1a in multiple cell types and promoting expression
of the master regulator of angiogenesis, vascular endothelial
growth factor (VEGF). VEGF expression can also be induced
by the transcriptional co-activator PGC1a upon nutrient depriva-
tion through an ERR-a-dependent, HIF1a-independent pathway
in muscle cells but not ECs (Arany et al., 2008), as well as by the
ATF4 transcription factor downstream of the integrated stress
response (ISR) triggered by either endoplasmic reticulum (ER)
stress or amino acid (AA) deprivation (Abcouwer et al., 2002).
VEGF acts on ECs via binding to the cell-surface tyrosine
kinase receptor VEGFR2, triggering an orchestrated cascade
of signal transduction via the PI3K andmitogen-activated protein
kinase (MAPK) pathways involving critical second messengers
nitric oxide (NO) and cyclic guanosine monophosphate (cGMP)
and changes in gene expression facilitating EC migration, prolif-
eration, and vessel formation (Olsson et al., 2006). VEGF-medi-
ated angiogenesis is potentiated by the NAD+-dependent
deacetylase SIRT1, which deacetylates and inactivates FOXO
transcription factors (Potente et al., 2007) involved in negative
regulation of EC migration and tube formation (Potente et al.,
2005). VEGF signaling also triggers changes in cellular energy
metabolism—namely increased glucose uptake and glycolysis
necessary to provide rapid energy for EC migration (De Bock
et al., 2013).Cell 173, 117–129, March 22, 2018 ª 2018 Elsevier Inc. 117
Hydrogen sulfide (H2S) is a proangiogenic gas (Cai et al., 2007;
Szabo´, 2007) produced in ECs upon VEGF stimulation (Papape-
tropoulos et al., 2009) primarily by the transsulfuration enzyme
cystathionine-g-lyase (CGL, a.k.a. CTH or CSE) (Wang, 2012).
Like NO, which—in addition to activating cGMP synthesis—
functions through post-translational modification (S-nitrosyla-
tion) of target proteins (Fukumura et al., 2006), H2S promotes
angiogenesis through S-sulfhydration and activation of proximal
signal transduction components, including VEGFR2 (Tao et al.,
2013) and endothelial nitric oxide synthase (eNOS) (Altaany
et al., 2014; Coletta et al., 2012). Angiogenesis is compromised
upon genetic CGL deficiency in aorta explant assays ex vivo (Pa-
papetropoulos et al., 2009) and arterial ligation in vivo (Kolluru
et al., 2015). However, mechanisms of CGL regulation in ECs
and the relative contribution of H2S versus NO in angiogenesis
remain unclear (Katsouda et al., 2016).
Dietary restriction (DR), defined as reduced nutrient/energy
intake without malnutrition, is best known for its ability to extend
lifespan, improve metabolic fitness, and increase stress resis-
tance (Colman et al., 2009; Fontana et al., 2010; Hine et al.,
2015). DR regimens, which vary widely, can emphasize either re-
striction of total food intake (calorie restriction, CR) or dilution of
specific nutrients in the diet, such as the sulfur AAs (SAAs) methi-
onine (M) and cysteine (C) (M restriction, MR) (Miller et al., 2005;
Orentreich et al., 1993). We recently reported that CR increases
hepatic CGL expression, endogenous H2S production capacity,
and resistance to hepatic ischemia reperfusion injury, each of
which is abrogated by dietary C supplementation (Hine et al.,
2015). CR also promotes revascularization and recovery from
femoral artery ligation in rodents (Kondo et al., 2009) and main-
tains vascular health in rodents and non-human primates in
part by preserving capillary density in skeletal muscle (Omodei
and Fontana, 2011). Interestingly, SIRT1 is activated in some tis-
sues upon DR (Canto´ and Auwerx, 2009; Wang, 2014) and
required for VEGF-dependent angiogenesis (Potente et al.,
2007). However, the effects of DR on angiogenesis and the po-
tential role of H2S remain unknown. Here, we identified SAA re-
striction as a proangiogenic trigger in ECs in vitro and in skeletal
muscle in mice in vivo.
RESULTS
SAA Restriction Induces Endothelial VEGF Expression
In Vitro and Functional Angiogenesis In Vivo
We tested the potential of isolated nutrient restriction indepen-
dent of ischemia or hypoxia to impact angiogenesis in vitro using
a model of SAA restriction (Hine et al., 2015). Human umbilical
vein ECs (HUVECs) cultured overnight in media lacking SAAs
(M&C) displayed increased VEGF mRNA expression and pro-
tein secretion into the media (Figure 1A). This correlated with
increased proangiogenic potential, including migration across
a scratch (Figure 1B), formation of capillary-like structures
(tube formation; Figure 1C), and increased sprout length in
three-dimensional HUVEC spheroid cultures—an effect that
was abrogated by the specific VEGFR2 inhibitor SU5416 (Fig-
ure 1D). Inhibiting SIRT1 activity with Ex-527 significantly
reduced HUVEC tube formation (Figure 1C) and branch point
number (Figure S1A) uponM&C, suggesting that the proangio-118 Cell 173, 117–129, March 22, 2018genic pathway triggered by M&C is dependent on both VEGF
and SIRT1 activity.
To test the impact of dietary SAA restriction on angiogenesis
in vivo, mice were given ad libitum access to an MR diet contain-
ing a limiting amount of M and lacking C (Miller et al., 2005; Oren-
treich et al., 1993). Young adult wild-type (WT) mice onMR for up
to 2monthsmaintained a lower bodyweight despite normal food
intake relative to mice fed a control diet containing normal M and
C levels (Figure S1B).
Strikingly, MR resulted in increased vascular density in skeletal
muscle as determined by immunohistochemistry (IHC) (Fig-
ure 1E) and flow cytometric analysis (Figure S1C) for the EC
marker CD31. Consistent with VEGF dependence, this effect
was blocked by axitinib, one of the best-characterized VEGF re-
ceptor inhibitors in vivo with demonstrated antiangiogenic activ-
ity in the context of tumor neovascularization (Ma and Waxman,
2008) (Figures 1E and S1C). Interestingly, although expression of
VEGF mRNA was not consistently affected upon MR in whole
gastrocnemius muscle (Figure S1D), there was a trend toward
increased VEGF protein in gastrocnemius muscle extracts
(Figure S1E). VEGF and CD31 co-localized in gastrocnemius
muscle by IHC (Figure S1F), consistent with ECs as the source
of VEGF upon MR in vivo as observed upon M&C in vitro
(Figure 1A).
Functional significance was tested in the context of femoral
artery ligation in mice preconditioned on MR or control diet
for 1 month prior to surgical occlusion and returned to a com-
plete diet after surgery (Figure S1G). Although blood flow was
similarly interrupted in both diet groups immediately after ligation
(d0), return of blood flow indicative of neovascularization was
accelerated in MR mice, with significant improvement by d3
after ligation (Figure 1F). CD31 IHC ofmuscle sections confirmed
a relative increase in capillary density in both ischemic and
non-ischemic legs of MR versus control mice despite a return
to a complete diet for 10 days (Figure 1G). Functional improve-
ment was also observed in mice preconditioned on a different
DR regimen—40% CR—for 1 month prior to femoral ligation
(Figures S1H and S1I). In addition to improved return of blood
flow (Figure S1H), CR mice demonstrated improved treadmill
exercise endurance testing on d4 after ligation (Figure S1I).
Together, these data suggest neovascularization induced by
DR (in the form of CR or MR) as a contributing factor in
the improved physiological response to acute blood flow
cessation.
GCN2-Dependent, Hypoxia-Independent Regulation of
VEGF and Angiogenesis upon SAA Restriction
Although HIF1a upon hypoxia is the best-characterized trigger
of VEGF expression in multiple cell types, including ECs,
increased VEGF expression upon M&C was unaffected by
HIF1a RNAi knockdown (KD) (Figures 2A and S2A) and coin-
cided with a trend toward reduced HIF1a protein expression
(Figures 2B and S2B). PGC1a can also induce VEGF indepen-
dently of HIF1a upon total nutrient/growth-factor deprivation
in myocytes but not ECs (Arany et al., 2008). Consistent
with this, endogenous PGC1a mRNA expression in HUVECs
was very low as judged by Ct value (data not shown) and
unaffected by M&C (Figure S2C), while exogenous PGC1a
Figure 1. SAA Restriction Induces Endothelial VEGF Expression In Vitro and Functional Angiogenesis In Vivo
(A) VEGFmRNA levels (left, n = 4 experiments per group) and secreted protein concentration in themedia (right, n = 6 experiments per group) of HUVECs cultured
in control (Ctrl) or SAA-deficient (M&C) media for 16 hr. Error bars indicate SEM.
(B) Migration assay: representative migration across a scratch (left, 103magnification at t = 20 hr; dotted lines indicate boundary of the scratch at t = 0 hr) and
area under the curve (AUC; right, n = 7–10 data points per condition, with each data point representing the mean of multiple measures within a single well in a
representative experiment) from HUVECs cultured in the indicated media.
(C) Tube formation assay: representative capillary-like structures (left, 403 magnification) and quantification of tube length/field in arbitrary units (AU; right,
n = 8–10 data points per condition) in HUVECs incubated in the indicated media ± SIRT1 inhibitor Ex-527 for 18 hr.
(D) Spheroid assay: representative images (left, 403 magnification) and quantification (right, in triplicate) of sprouting HUVEC spheroids in the indicated
media ± VEGFR2 inhibitor SU5416 for 24 hr. Blue, DNA (DAPI); red, F-actin (phalloidin).
(E) Representative transverse sections (left, 403magnification) and quantification (right) of gastrocnemiusmuscle stained for endothelial marker CD31 inmice fed
for 2 weeks on control or MR diet ± VEGFR2 inhibitor axitinib; n = 6–8 mice per group.
(F) Longitudinal Doppler imaging of blood flow in WT mice preconditioned for 1 month on control or MR diet prior to femoral artery ligation (I, ischemic; NI, non-
ischemic). Representative infrared images on the indicated day after ligation (left). Quantification of blood flow recovery with individual animal AUCs used for
statistical comparison (right, n = 7–8 mice per group).
(G) Representative transverse sections (left, 403 magnification) and quantification (right) of CD31-stained gastrocnemius muscle 10 days after ligation from
(F); n = 4 mice per group.
Error bars indicate SD unless otherwise noted; asterisks indicate the significance of the difference by Student’s t test or one-way ANOVA with Sidak’s multiple
comparisons test between diets in vivo or SAA deprivation in vitro; *p < 0.05, **p < 0.01, ***p < 0.001. See also Figure S1.overexpression in HUVECs failed to modulate VEGF expression
(Figures S2D and S2E).
The AA starvation response (AASR), a branch of the ISR
involving binding of uncharged cognate tRNAs to the general
control nonderepressible 2 (GCN2) kinase, phosphorylation of
eukaryotic translation initiation factor 2a (eIF2a), and translationalderepression of ATF4 (Kilberg et al., 2005; Wek et al., 1995), has
been implicated in DR-mediated resistance to ischemia reperfu-
sion injury (Peng et al., 2012) but has not been assessed inECs. In
HUVECs,M&C increased eIF2a phosphorylation, ATF4 protein
expression, and transcription of the ATF4 target, Asns (Figures
2B, S2B, and S2F). ATF4 small interfering RNA (siRNA) reducedCell 173, 117–129, March 22, 2018 119
Figure 2. GCN2-Dependent, Hypoxia-Independent Regulation of VEGF and Angiogenesis upon SAA Restriction
(A) Relative VEGFmRNA expression in HUVECs 2 days after transfection with HIF1a siRNA or control scrambled (Sble) siRNA and cultured in control (Ctrl) or SAA-
deficient (M&C) media for 16 hr; n = 5 experiments per group. Error bars indicate SEM.
(B) Immunoblots of HIF1a, eIF2a (p-Ser51, total), and ATF4 in HUVECs cultured as indicated for 16 hr.
(C) Relative VEGF mRNA expression in HUVECs 2 days after transfection with ATF4 or Sble siRNA and cultured as indicated for 16 hr; n = 4 experiments
per group. SEM.
(D and E) Relative HUVEC VEGF mRNA expression (D, n = 3 experiments per group; SEM) and secreted VEGF protein concentration in media (E, n = 3–6
experiments per group; SEM) 2 days after transfection with ATF4 overexpression (ATF4OE) or control construct (Empty).
(F and G) VEGFmRNA expression (F) and spheroid formation (G) in WT and GCN2KO primary mouse ECs from n = 3 mice per genotype cultured as indicated for
16 hr. For the sprouting assay (G), representative images (left, 403 magnification) and quantification (right) of WT and GCN2KO EC spheroids cultured in the
indicated media for 24 hr. Blue, DNA (DAPI); red, F-actin (phalloidin); AU, arbitrary units.
(H) Representative transverse sections (left, 403magnification) and quantification (right) of CD31-stained gastrocnemius muscle in WT or GCN2KO mice fed for
2–4 weeks on control or MR diet; n = 5–6 mice per group.
(I) VEGF mRNA in MDFs, MEFs, or C2C12 myotubes cultured as indicated for 16 hr; n = 4–6 experiments per group; SEM.
(J) VEGF mRNA expression in WT and GCN2KO primary mouse skeletal myotubes (n = 5 mice per genotype tested at two different passages) cultured as
indicated for 16 hr.
(K) Immunoblots of HIF1a, PGC1a, eIF2a (p-Ser51, total), and ATF4 in C2C12 myotubes cultured as indicated for 16 hr.
Error bars indicate SD unless otherwise noted; asterisks indicate the significance of the difference by Student’s t test or one-way ANOVA with Sidak’s multiple
comparisons test between diets in vivo or SAA deprivation in vitro; *p < 0.05, **p < 0.01, ***p < 0.001. See also Figure S2.VEGFandAsns transcriptional upregulation uponM&C (Figures
2C and S2F), while ATF4 overexpression increased VEGF and
Asns mRNA expression (Figures 2D and S2G–S2I) and VEGF
secretion into the media (Figure 2E) independent of nutrient
deprivation.
The requirement for GCN2 was tested in primary ECs isolated
fromWT(FigureS2J)andGCN2knockout (GCN2KO)mice.Similar
to HUVECs, -M&C significantly increased VEGF and Asns mRNA120 Cell 173, 117–129, March 22, 2018expression (Figures 2F and S2K) and sprout length (Figure 2G) in
WTbut notGCN2KOECs. In vivo,GCN2KOmice failed to increase
vascular density upon 2–4 weeks of MR compared to controls
(Figure 2H).
M&C also increased VEGF mRNA expression in primary
mouse dermal fibroblasts (MDFs), immortalized mouse embry-
onic fibroblasts (MEFs) and C2C12 myotubes (Figure 2I). In pri-
mary skeletal myotubes, VEGF induction upon M&C required
Figure 3. VEGF Signaling and AASR Converge on Endothelial H2S Production by CGL
(A) Representative H2S production capacity as indicated by black lead sulfide formation fromHUVECs upon VEGF (50 ng/mL) orM&C treatment in the presence
or absence of the CGL inhibitor PAG (100 mM) as indicated for 16 hr.
(B) Representative (left) endogenous H2S levels (blue, H2S [P3 fluorescence]; red, DNA [DRAQ5]) and quantification of P3 intensity (right) in HUVECs upon
VEGF orM&C treatment. n = 4 wells per treatment with 4–6 images per well; one-way ANOVA with Sidak’s multiple comparisons test versus control (asterisks)
or ± PAG within treatment (carets).
(C) CGL mRNA expression in WT and GCN2KO primary mouse ECs cultured from n = 3 mice per genotype in control (Ctrl) or M&C media for 16 hr.
(D) CGL mRNA expression in HUVECs 2 days after transfection with ATF4 siRNA or control scrambled (Sble) siRNA and cultured in the indicated media for 16 hr.
n = 4 experiments per group; SEM.
(E) CGL mRNA Expression in HUVECs 2 days after transfection with ATF4 overexpression or control (empty) plasmid. n = 3 experiments per group; SEM.
(F and G) Representative images (left, 403magnification) and quantification (right, in triplicate) of spheroids cultured from (F) HUVECs in control orM&Cmedia
for 24 hr in the presence of vehicle (Veh) or PAG and (G) WT or CGLKO primary EC sprouts in control or M&C media for 24 hr. Blue, DNA (DAPI); red, F-actin
(phalloidin); AU, arbitrary units.
Unless otherwise indicated, error bars indicate SD, and asterisks indicate the significance of the difference between diets in vivo or SAA levels in vitro by Student’s
t test or one-way ANOVA with Sidak’s multiple comparisons test; *p < 0.05, **p < 0.01, ***/p < 0.001. See also Figure S3.GCN2 (Figure 2J). In MDFs, ATF4 short hairpin RNA (shRNA)
prevented the increase in VEGF mRNA by M&C (Figure S2L).
In C2C12 myotubes, VEGF induction coincided with increased
eIF2a phosphorylation and ATF4 expression and reduced
HIF1a protein levels (Figure 2K). Notably, VEGF induction
upon M&C in C2C12 myotubes was unaffected by HIF1a
RNAi KD under normoxic (20%) or hypoxic (<1%) oxygen
tensions (Figures S2M–S2O). PGC1a RNAi KD also failed
to dampen VEGF induction upon M&C in C2C12 myotubes
(Figure S2P).
Taken together, these data reveal SAA restriction and the
GCN2/ATF4-dependent AASR as a novel trigger of increased
VEGF expression and angiogenesis independent of hypoxia,
HIF1a, or PGC1a.
VEGF Signaling and AASR Converge on Endothelial H2S
Production by CGL
VEGF promotes angiogenesis in part by stimulating CGL-depen-
dent production of the proangiogenic gas H2S in ECs (Papape-
tropoulos et al., 2009); however, mechanisms of CGL regulationin ECs and the importance of H2S in angiogenesis remain poorly
understood. H2S production capacity (Figure 3A) and endoge-
nous H2S levels (Figure 3B) were similarly increased by M&C
and exogenous VEGF addition and were sensitive to the CGL in-
hibitor propargylglycine (PAG).M&Calso boosted endogenous
H2S production in primary hepatocytes, while VEGF did not,
because hepatocytes lack VEGFR2 (Figure S3A).
CGL is an ATF4 target downstream of the ISR triggered either
by ER stress in MEFs (Dickhout et al., 2012) or C deprivation in
HepG2 cells (Lee et al., 2008). In primary mouse ECs, CGL
mRNAwas strongly induced uponM&C (Figure 3C). This effect
was abrogated in ECs lacking GCN2 (Figure 3C) or in HUVECs
upon ATF4 KD (Figures 3D and S2F), while ATF4 overexpression
increased CGL independent of SAA deprivation (Figure 3E).
Importantly, VEGF mRNA was not affected by the absence of
CGL (Figure S3B) in vitro, consistent with CGL and VEGF as in-
dependent downstream targets of the AASR. Interestingly, exog-
enous VEGF increased CGL mRNA (Figure S3C) and protein
(Figure S3D) expression in HUVECs independent of nutrient
deprivation, suggestive of a positive feedback loop betweenCell 173, 117–129, March 22, 2018 121
Figure 4. CGL Required for Angiogenesis In Vivo
(A) Representative transverse sections (203 magnification) of gastrocnemius muscle from WT and CGLKO mice stained for CD31 and endogenous H2S.
(B) Quantification of endogenous H2S in CD31
+ ECs in the gastrocnemius muscle of WT and CGLKO mice fed for 2 weeks on control or MR diet as indicated;
n = 4–5 mice per group, with quantification of 3–10 images per mouse.
(C) Representative transverse sections (left, 403magnification) and quantification (right) of CD31-stained gastrocnemius muscle from WT and CGLKO mice fed
for 2 weeks on control or MR diet as indicated; n = 4 mice per group.
(D) Representative transverse sections of CD31-stained gastrocnemiusmuscle (left, 403magnification) and quantification (right) 2weeks after Ad-null or Ad-CGL
injections. n = 3–4 mice per group; Student’s t test.
(E) Representative transverse sections (left, 403 magnification) and quantification (right) of CD31-stained gastrocnemius muscle from WT and CGLKO mice
subjected to low-intensity exercise (Run) versus sedentary controls (Sed) for 1 month; n = 4–5 mice per group.
(F) Representative transverse sections of CD31-stained gastroc (left, 403magnification) and quantification (right) fromWT and CGLKOmice 6 days after the final
intramuscular injection of control (Ad-null) or VEGF165 -expressing (Ad-VEGF) adenovirus; n = 4 mice per group.
Error bars indicate SD; asterisks indicate the significance of the difference between diets or treatments within genotype by one-way ANOVAwith Sidak’s multiple
comparisons test unless otherwise noted; *p < 0.05, **p < 0.01, ***p < 0.001. See also Figure S4.VEGF and CGL expression, but without affecting expression of
the two other H2S-generating enzymes, CBS or 3-MST.
The functional relevance of endothelial CGL in angiogenic
potential in vitro was assessed in the EC spheroid assay.
Increased sprout length of EC spheroids upon M&C was
prevented by the CGL inhibitor PAG in HUVEC (Figure 3F)
and in CGL knockout (CGLKO) mouse ECs (Figure 3G).
Thus, CGL is required for angiogenesis induced by M&C
in vitro.
CGL Required for Angiogenesis In Vivo
We next tested the requirement for CGL-derived H2S in angio-
genesis triggered by MR in vivo. Consistent with CGL as the
major H2S producer in EC in vivo (Wang, 2012), P3 fluorescence
indicative of endogenous H2S production co-localized with
CD31+ cells in fresh-frozen sections of gastrocnemius muscle
from WT but not CGLKO mice (Figure 4A). Quantification of P3
intensity in WT and CGLKO mice fed control versus MR diet
for 2 weeks confirmed a CGL-dependent increase in EC H2S
production upon MR in vivo (Figure 4B). Coincident with failure
to increase H2S, CGLKOmice failed to increase capillary density
upon MR in vivo relative to WT mice (Figure 4C). Furthermore,
the CGL inhibitor PAG partially prevented 40% CR from122 Cell 173, 117–129, March 22, 2018improving recovery from femoral ligation (Figures S1H and
S1I). Taken together, these data are consistent with a require-
ment for CGL-derived H2S for angiogenesis triggered by nutrient
deprivation.
We next asked if CGL-derived H2S is sufficient to promote
angiogenesis independent of SAA restriction. To this end, we in-
jected CGL-expressing adenovirus into the gastrocnemius mus-
cle ofWTmice via intra-muscular injection, likely resulting in CGL
overexpression in both myotubes and ECs due to the ability of
the Ad5 serotype to infect multiple cell types. Local CGL viral
transduction increased muscle H2S production capacity (Fig-
ure S4A) and vascular density (Figure 4D) independent of any
other proangiogenic stimulus, suggesting that an increase in
CGL-derived H2S is sufficient to trigger angiogenesis.
To test this apparent general requirement for CGL in angio-
genesis independent of the upstream stimulus, we induced
angiogenesisbyeither treadmill exercise trainingorbyVEGFover-
expression via intra-muscular injection of VEGF-overexpressing
(ad-VEGF165) adenovirus. Exercise training increased endoge-
nous VEGF mRNA expression in WT mice (Figure S4B), while
both exercise training (Figure 4E) and local VEGF overexpression
via adenoviral genedelivery (Figure 4F) increasedcapillary density
in WT but not CGLKO mice. Taken together, these data indicate
that CGL is necessary for VEGF-mediated neovascularization
in vivo independent of the upstream proangiogenic stimulus.
H2S Promotes Glucose Uptake and ATP Generation by
Glycolysis for EC Migration
Because CGL is a promiscuous enzyme that can convert cysta-
thionine to C as part of the transsulfuration pathway (TSP) but
can also use C to produceH2S and serine, we soughtmore direct
evidence of H2S as the CGLmetabolite relevant to angiogenesis.
H2S addition to standard EC media in the form of NaHS
increased proliferation (Figure S5A) and migration across a
scratch (Figure 5A). This latter effect was only partially blocked
with mitomycinC (MitoC), consistent with migration as a critical
factor in H2S-induced proangiogenic potential. In support of
this, HUVECs overexpressing CGL (Ad-CGL) formed lamellipo-
dial projections over larger areas (Figure 5B) coincident with
increased migration speed and greater cell body displacement
(Figure 5C).
Cell migration requires rapid ATP generation to facilitate actin
cytoskeleton rearrangement, which in ECs is met by increasing
glycolytic metabolism (De Bock et al., 2013; Schoors et al.,
2014). We thus examined glucose uptake and glycolytic ATP
production as a function of genetic and pharmacological H2S
modulation. Treatment for 30 min with NaHS increased glucose
uptake in HUVECs similar to VEGF (Figure 5D). Interestingly,
H2S-induced glucose uptake was independent of SIRT1 in
mouse ECs (Figure S5B).
Glycolytic activity was assessed using several methods.
Extracellular acidification rate (ECAR), a surrogate marker of
glycolysis, was increased by NaHS treatment in HUVECs (Fig-
ure S5C). In primary ECs from WT mice, NaHS and VEGF
increased ECAR to a similar level (Figures 5E and S5D), while
in CGLKO ECs, ECAR was significantly reduced at baseline
and increased by NaHS but not VEGF administration (Figure 5E).
Interestingly, accumulation of the end product of aerobic glycol-
ysis, lactate, in the media following NaHS treatment did not
reach the level of statistical significance (Figure S5E). We thus
measured glycolysis directly using the release of 3H2O from
C5-3H-glucose and found a significant increase upon NaHS or
VEGF treatment (Figure 5F) beginning after 30 min (Figure S5F).
Consistent with increased glycolysis, H2S boosted intracel-
lular ATP levels over a rapid time course similar to exogenous
VEGF (Figure 5G). Both exogenous H2S addition and CGL over-
expression also increased EC migration, and this was sensitive
to competitive inhibition of glycolysis by 2-deoxy-D-glucose
(2-DG; Figures 5H and 5I). Together, these data support the
functional relevance of CGL-derived H2S in activation of glyco-
lytic ATP generation necessary for proangiogenic migratory
behavior.
Steady-state flux analysis was employed to better understand
glucose disposal upon NaHS treatment. Addition of 13C1,2-
glucose to the media for the final 15 min of a 2-hr NaHS treat-
ment revealed significant changes in labeling of glycolytic
intermediates, including an increase in glyceraldehyde-3-phos-
phate, dihydroxy-acetone-phosphate, and fructose-phosphate
(Figure 5J). Interestingly, a significant increase was also
observed in the pentose phosphate pathway (PPP) and purine
biosynthetic intermediates, including sedoheptulose-7P, phos-phoribosyl-1-pyrophosphate, and inosine monophosphate
(IMP) (Figure 5J). A significant increase in total unlabelled glyco-
lytic and nucleotidemetabolites was also observed (Figure S5G).
Increased glucose flux through the PPP is required for angio-
genesis (Bierhansl et al., 2017; Viza´n et al., 2009) and could
also contribute to increased ECAR via CO2 release during the
oxidative phase of the reaction (Figures 5E and S5C) but is
not mutually exclusive with the observed increase in glycolytic
ATP generation.
Finally, we asked if NaHS and M&C removal triggered similar
metabolic responses as predicted if endogenous H2S production
upon M&C is important for its proangiogenic action. To this
end, we performed unbiased metabolomic analyses of HUVECs
cultured under standardized media conditions (complete DMEM
supplemented with dialyzed fetal bovine syndrome [FBS] and EC
growth factors) for 1 hr before addition of NaHS or M&C removal.
A comparison of global profiles over a time course following treat-
ment revealed a time-dependent shift upon M&C away from
the control and a striking convergence after 4 hr with the 15-min
NaHS profile (Figure 5K). An analysis of all significant changes in
the same direction between the 15-min NaHS and M&C groups
included glycolytic and PPP intermediates (Figure 5L).
H2S Shifts Oxidative/Glycolytic Balance Concomitant
with Inhibition of Mitochondrial OXPHOS
By what mechanism does H2S promote glucose uptake and
disposal in ECs? Increased ECAR by NaHS was unaffected
by axitinib or the eNOS competitive antagonist L-nitroarginine
methyl ester (L-NAME) (Figure S5H). Similarly, NaHS-induced
EC migration was unaffected by L-NAME (Figure S5I) or genetic
eNOS KD (Figures S5J and S5K), together suggesting a mecha-
nism of action either independent or downstream of proximal
VEGFR2 signaling.
In many cell types, inhibition of mitochondrial oxidative
phosphorylation (OXPHOS) and transient ATP depletion initiates
adaptive responses, including AMP-activated protein kinase
(AMPK) activation, that boost glucose uptake and glycolytic
ATP production (Hardie et al., 2016). At high concentrations,
H2S can inhibit complex IV of the mitochondrial electron trans-
port chain (ETC) and prevent ATP generation by OXPHOS (Smith
et al., 1977); however, whether this mechanism of action contrib-
utes to its proangiogenic effect is unknown. Despite the fact that
ECs rely predominantly on glycolysis (De Bock et al., 2013), we
observed significant changes in glucose flux through the citric
acid cycle (reduced citrate/isocitrate and oxaloacetate; Fig-
ure 5J), as well as reduced total citrate (Figure S5G), suggesting
a block in mitochondrial OXPHOS without an increase in cell
death (Figure S5L). Interestingly, labeled and total malate were
increased in the same analyses, possibly due to an increase in
the cytoplasmic pool, which cannot be distinguished from the
mitochondrial pool in whole-cell lysates.
CGLKO ECs displayed increased oxygen consumption rate
(OCR) under basal conditions relative to WT cells (Figure 6A),
consistent with the ability of endogenous H2S to inhibit mito-
chondrial ETC activity. Similarly, exogenous H2S decreased
OCR concomitant with an increase in ECAR to the same levels
as the complex V inhibitor oligomycin (Figure 6B). To confirm
the predicted effects of H2S on complex IV activity, OCR wasCell 173, 117–129, March 22, 2018 123
Figure 5. H2S Promotes Glucose Uptake and ATP Generation by Glycolysis for EC Migration
(A) Representative migration across scratch (left, 103 magnification) and quantification (right) of HUVECs ± 100 mM NaHS in the presence of vehicle or
mitomycin C (MitoC, 1 mg/mL) to inhibit proliferation. n = 12 wells each from cells at two different passages; one-way ANOVA with Sidak’s multiple comparisons
test between control and NaHS within vehicle or MitoC treatment group.
(B and C) Representative images (B) and quantification (C) of migration speed (left, n = 5–7 cells per condition) and distance (right, n = 5–7 cells per condition in
x and y directions) from time-lapse video imaging of GFP+ HUVECs infected with control (Ad-null) or CGL adenovirus (Ad-CGL) as indicated; Student’s t test.
(D) Relative glucose uptake in HUVECs pretreated with NaHS or 50 ng/mL VEGF for 1 hr. n = 3–6 experiments per group; one-way ANOVAwith Dunnett’s multiple
comparisons test. Error bars indicate SEM.
(E) ECAR in WT and CGLKO primary mouse ECs pretreated for 1 hr with VEGF or NaHS. 10 technical replicates from ECs pooled from six mice per genotype;
one-way ANOVA with Sidak’s multiple comparisons test as indicated.
(F) Glycolytic flux in HUVECs pretreated for 3 hr with NaHS or VEGF. Representative experiment of six with n = 3 per group; one-way ANOVA with Dunnett’s
multiple comparisons test.
(G) Time-dependent ATP production in HUVECs pretreated with NaHS or 1 mM 2-DG at t = 0. n = 4 experiments each for NaHS and VEGF and 2 for 2-DG; error
bars indicate SEM; two-way ANOVA with Dunnett’s multiple comparisons test relative to t = 0 (asterisk, NaHS; caret, VEGF; pound sign, 2-DG).
(H and I) Representativemigration (left, 103magnification) and quantification (right, AUC) of HUVECs treated ±NaHS (H, n = 11 technical replicates per condition)
or infected with a control (Ad-null) or CGL adenovirus (Ad-CGL) at a multiplicity of infection of 50 (I, n = 5–6 technical replicates per condition) in the presence of
vehicle or 2-DG; one-way ANOVA with Sidak’s multiple comparisons test between control and NaHS or Ad-Null and Ad-CGL within 2-DG or vehicle treat-
ment group.
(J) Log2 fold change of C13-labeled metabolites in HUVECs measured by mass spectrometry after 1 hr of NaHS pretreatment compared to control. Red dots,
metabolites with false discover rate (FDR) adjusted p < 0.05 and absolute value of log2 fold change >1.2; blue dots, metabolites with FDR adjusted p > 0.05 and/or
absolute value of log2 fold change <1.2.
(K) Plot of the first two components of orthogonal partial least squares discriminant analysis on unlabeled metabolite levels in HUVECs after 15-min, 2-hr, or 4-hr
treatment with NaHS or M&C. Ellipses represent 99% confidence bound for treatment groups.
(L) Average metabolite log2 fold changes after 15 min of NaHS or M&C. All metabolites that significantly (p < 0.05) changed in the same direction in both
treatment groups are shown.
Error bars indicate SD unless otherwise indicated; */ p^ < 0.05, **p < 0.01, ***/###p < 0.001, ####p < 0.0001. See also Figure S5.
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Figure 6. H2S Shifts Oxidative/Glycolytic Balance Concomitant with Inhibition of Mitochondrial OXPHOS
(A) Basal OCR in WT and CGLKO primary mouse ECs. n = 10 technical replicates from ECs pooled from six mice per genotype; Student’s t test.
(B) OCR (left) and ECAR (right) in HUVECs pretreated for 2 hr with 100 mM NaHS followed by oligomycin (oligo, 2.5 mM) injection at the indicated time. Repre-
sentative experiment with n = 10 technical replicates per treatment.
(C) Mitochondrial complex activity in permeabilized HUVECs pretreated for 1 hr with NaHS or 10 mM KCN; representative experiment with n = 6 technical
replicates; one-way ANOVA with Sidak’s multiple comparisons test within complex activity group.
(D and E) Immunoblots of acetyl-coenzyme A carboxylase (ACC) (pSer79, total) and AMPK (pThr172, total) in HUVECs treated with NaHS (D) or KCN (E) for the
indicated time.
(F) ECAR in HUVECs pretreated for 1 hr with NaHS ± 10 mM compound C (Comp C, an AMPK inhibitor) as indicated. n = 10 technical replicates from ECs pooled
from six mice per genotype; one-way ANOVA with Sidak’s multiple comparisons test between NaHS treatment within Comp C treatment group.
(G) Relative glucose uptake in HUVECs pretreated with the indicated agent for 1–3 hr. n = 2–8 experiments per group; error bars indicate SEM; one-way ANOVA
with Dunnett’s multiple comparisons test.
(H) ECAR in HUVECs pretreated for 2 hr with KCN, 2 mM oligo, or phenformin (Phen, 500 mM) expressed as a percent of control over time after addition of 10 mM
glucose. n = 12–19 technical replicates; one-way ANOVA with Dunnett’s multiple comparisons test.
(I) Migration across scratch expressed as fold change relative to control in HUVECs treated with oligomycin (2 mM), phenformin, or KCN ± 2-DG (1 mM) as
indicated. n = 5–12 AUC values per group each from cells at different passages; one-way ANOVA with Sidak’s multiple comparisons test versus control without
2-DG treatment.
Error bars indicate SD unless otherwise noted; *p < 0.05, **p < 0.01, ***p < 0.001. See also Figure S6.measured in isolated HUVEC mitochondria in the presence of
NaHS or the complex IV inhibitor potassium cyanide (KCN). In
addition to the expected decrease in OCR in the presence ofthe complex IV substrate TMPD-ascorbate, NaHS also reduced
oxygen consumption fueled by pyruvate, consistent with addi-
tional ETC inhibition at complex I (Figure 6C).Cell 173, 117–129, March 22, 2018 125
Figure 7. Model for Regulation of Angiogenesis by SAA Restriction
GCN2/ATF4 pathway activation in ECs by SAA restriction induces VEGF
expression, as well as CGL-mediated H2S production, with effects on glucose
uptake and utilization via glycolysis and PPP required for EC migration and
proliferation.We next asked if complex IV inhibition was sufficient to trigger
AMPK activation in ECs. AMPK was activated within 5 min of
NaHS or KCN treatment (Figures 6D and 6E) and returned to
baseline after 30 min. Treatment with an AMPK inhibitor
(compound C) prevented the increase in ECAR (Figure 6F),
glucose uptake, and migration (Figures S6A and S6B). Consis-
tent with the rapid and transient nature of AMPK activation,
10-min NaHS treatment was sufficient to promote EC migration
during the subsequent 12-hr period, and this was blocked by
compound C (Figures S6C and S6D).
To determine if energy stress was the proximal trigger to
AMPK activation, we measured ATP/ADP ratio over a time
course following NaHS addition, as well as energy charge
15min after NaHS addition, but observed no significant changes
(Figures S6E and S6F). AMPK can also be activated by upstream
kinases, such as CamKKb (Lee et al., 2012), or reactive oxygen
species (ROS) upon hypoxia (Emerling et al., 2009) or nutrient/
energy deprivation (Li et al., 2013). However, NaHS-mediated
glucose uptake was unaffected by the CamKKb inhibitor STO-126 Cell 173, 117–129, March 22, 2018609 (Figure S6G), while mitochondrial ROS failed to increase
upon NaHS or KCN treatment (Figure S6H).
Nonetheless, if inhibition of mitochondrial ATP synthesis is the
trigger by which H2S promotes AMPK activation, glycolytic ATP
production, and angiogenesis, then any ETC inhibitor could have
similar proangiogenic effects. Consistent with this hypothesis,
multiple ETC inhibitors targeting different complexes, as well
as the uncoupler FCCP, increased glucose uptake (Figure 6G),
albeit with slightly different kinetics (Figure S6I). ECAR (Figures
6H and S6J) and glycolytic flux (Figure S6K) were also stimulated
by OXPHOS inhibition. Finally, multiple ETC inhibitors stimulated
2-DG-sensitive EC migration (Figures 6I and S6L). Together,
these data are consistent with a mechanism of H2S action
in angiogenesis involving transient inhibition of mitochondrial
respiration by direct inhibition of ETC, resulting in increased
glucose uptake and a shift from OXPHOS to glycolysis and PPP.
DISCUSSION
SAA Restriction as a Proangiogenic Trigger
Amodel for the proangiogenic pathway activated by SAA restric-
tion and controlled by the GCN2-/ATF4-dependent AASR inde-
pendent of hypoxia, HIF1a, or PGC1a in ECs is presented in
Figure 7. While ATF4 regulation of VEGF expression has been re-
ported in the context of the ISR activated by AA deprivation or ER
stress in a human retinal pigmented EC line in vitro (Abcouwer
et al., 2002) or bymutation of tRNA synthetase genes in zebrafish
in vivo (Castranova et al., 2016), it has not been previously linked
to SAA deprivation via GCN2 in ECs. ATF4 can also activate CGL
and H2S production, which can feed back to increase eIF2a
phosphorylation and further activate the ISR (Yadav et al.,
2017). Future studies will be required to determine the impact
of AA deprivation on other proangiogenic factors, such as fibro-
blast growth factor (FGF), and if there is any specificity to SAAs.
Furthermore, while ATF4 can activate VEGF andCGL expression
in multiple different primary cell types in vitro, it remains to be
determined which cell types in vivo are critical for the proangio-
genic effects of SAA restriction.
Although H2S can also be generated by other enzymes,
including CBS or 3-MST, we found a genetic requirement for
CGL in angiogenesis triggered by nutrient deprivation, exercise,
or VEGF injection (Figure 4). CGL is also critical for de novo C
biogenesis via TSP, linkingMcyclemetabolitesupstream togluta-
thione and taurine production downstream, perturbation of any of
which could potentially contribute to the observed effects. Finally,
we acknowledge the apparent paradox of increased endogenous
H2S production in response to restriction of its substrate, C. How-
ever, as the source of free C for H2S generation by CGL is not
currently known, it could come from pools distinct from diet-
derived or de novo-produced C. For example, cytoplasmic gluta-
thione levels that are in themMrange could be utilized as a source
of freeC, ascouldproductsofproteosomalproteindegradationor
lysosomal autophagy. In support of this latter notion, the increase
in H2S production induced by growth factor (serum) withdrawal
in cultured cells is partially abrogated by genetic or pharma-
cological inhibition of autophagy (Hine et al., 2017), while the ben-
efits of MR on longevity in yeast require autophagy (Ruckenstuhl
et al., 2014).
In an accompanying manuscript, Das et al. (2018) report an
interaction between H2S and SIRT1 in the regulation of angio-
genesis as evidenced by the ability of H2S/NMN supplementa-
tion in old mice to reverse age-associated loss of muscle
vascular density and improved exercise performance. Although
the mechanism by which H2S augments SIRT1 function remains
to be elucidated, these data suggest that H2S and SIRT1 func-
tion in a critical axis regulating angiogenesis with the potential
tomitigate or reverse oxidative stress-induced and aging-related
changes in vascular health using pharmacological agents.
Mechanisms of H2S Regulation of Energy Metabolism
in ECs
H2S at physiological levels is thought to exert its biological activ-
ities through non-mutually exclusive mechanisms, including
post-translational modification of target proteins via S-sulfhydra-
tion of surface-exposed C residues (Mishanina et al., 2015; Mus-
tafa et al., 2009), direct or indirect antioxidant action (Whiteman
et al., 2004; Whiteman et al., 2005), or ATP generation via trans-
fer of electrons to the mitochondrial SQR protein (Goubern et al.,
2007; Yong and Searcy, 2001). There is clearly precedent for the
potential of H2S to regulate angiogenesis via S-sulfhydration of
target proteins in multiple pathways implicated in angiogenesis,
ranging from VEGFR2 signaling (Altaany et al., 2014; Coletta
et al., 2012; Tao et al., 2013) to cellular energy metabolism via
activation of the rate-limiting glycolytic enzymeGAPDH (Mustafa
et al., 2009).
H2S can also inhibit terminal electron transfer to oxygen (Nich-
olls and Kim, 1982) at supraphysiological levels, estimated to be
greater than 20 mM upon acute treatment of intact human colon
carcinoma ECs (Leschelle et al., 2005). Our data are consistent
with the potential relevance of this mechanism in regulation of
EC oxidative/glycolytic energy balance, although whether levels
of endogenously generated H2S upon SAA deprivation here or in
other contexts reach this inhibitory concentration remains un-
clear (Cooper and Brown, 2008). Consistent with our findings
in ECs, an increase in H2S in pancreatic b cells exposed to ER
stress promotes aerobic glycolysis associated with decreased
OXPHOS and increased S-sulfhydration of enzymes involved in
energy metabolism (Gao et al., 2015). Interestingly, a number of
tumors and cancer cells lines also upregulate GCN2 (Lehman
et al., 2015; Wang et al., 2013) or H2S production (Bhattacharyya
et al., 2013; Sen et al., 2015; Sonke et al., 2015; Szabo et al.,
2013), possibly contributing to theWarburg effect through inhibi-
tion of mitochondrial respiration.
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Antibodies
Anti-pT172-AMPK Cell Signaling Cat# 2535
Anti-AMPK Cell Signaling Cat# 2532
Anti-ACC1 Cell Signaling Cat# 4190
Anti-CGL (Anti-Cystathionase) Abcam Cat# Ab151769
Anti-CBS Abcam Cat# Ab135626
Anti-3MST (Anti-MPST) Sigma Cat# HPA001240
Anti-ATF4 (Anti-CREB-2) Santa Cruz Cat# Sc-200
Anti-beta Tubulin Cell Signaling Cat# 2128
Anti-Actin Cell Signaling Cat# 4970
HRP conjugated anti-rabbit Dako Cat# P044801-2
Anti-CD31 BD Bioscience Cat# 557355
Anti-HIF1a Cayman Chemical Cat# 10006421
Anti-p-eIF2a Ser51 Cell Signaling Cat# 9712S
Anti-total eIF2a Cell Signaling Cat# 9722S
Anti-Tubulin Cell Signaling Cat# 2146S
Anti-CD31-APC Biolegend Cat# 102410
Alexa Fluor 555 phalloidin ThermoFisher Cat# A34055
Bacterial and Virus Strains
Ad-CMV-CGL (Ad-mCTH) Vector Biolabs Cat# ADV-256305
Ad-CMV-Null Vector Biolabs Cat# 1300
Ad-h-VEGFA165 Vector Biolabs Cat# ADV-227457
Ad-m-ATF4-shRNA Vector Biolabs Cat# shADV-253208
Ad-GFP Vector Biolabs Cat# 1060
Biological Samples
Livers (frozen) taken from experimental
mouse strains listed in the Experimental
Models: Organisms/Strains section
See Experimental Models:
Organisms/Strains section
See Experimental Models:
Organisms/Strains section
Serum/Plasma (frozen) taken from
experimental mouse strains listed in the
Experimental Models: Organisms/Strains
section
See Experimental Models:
Organisms/Strains section
See Experimental Models:
Organisms/Strains section
Skeletal muscle (frozen) taken from
experimental mouse strains listed in the
Experimental Models: Organisms/Strains
section
See Experimental Models:
Organisms/Strains section
See Experimental Models:
Organisms/Strains section
Chemicals, Peptides, and Recombinant Proteins
NaHS Sigma Cat# 161527
GYY4137 Sigma Cat# SML0100
DL-Propargylglycine Sigma Cat# P7888
Passive Lysis Buffer (5x) Promega Cat# E1941
PLP (Pyridoxal 50-phosphate) Sigma Cat# P9255
L-cysteine Sigma Cat# C7352
Lead (II) acetate trihydrate Sigma Cat# 316512
P3 H2S Detection Probe From the lab of Prof. K.H. Ahn Singha et al., 2015
SU5146 Tocris Cat# 3037
(Continued on next page)
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Ex-527 Cayman Chemical Cat# 10009798
VECTASHIELD Antifade Mounting Medium
with DAPI
Vector laboratories Cat# H-1200
Potassium Cyanide Sigma Cat# 11813
Phenformin Sigma Cat# P7045
2-Deoxy-D-Gucose Sigma Cat# D8375
Oligomycin A Sigma Cat# 75351
FCCP (Carbonyl cyanide 4-(trifluoromethoxy)
phenylhydrazone)
Sigma Cat# C2920
Antimycin A Sigma Cat# A8674
MitomycinC Sigma Cat# M4287-2MG
Compound C (Dorsomorphin) Abcam Cat# Ab120843
Axitinib Selleckchem Cat# S1005
L-NAME (hydrochloride) Cayman Chemical Cat# 80210
Recombinant human VEGF165 Peprotech Cat# 100-20
Recombinant murine VEGF165 Peprotech Cat# 450-32
Propidium Iodine ThermoFisher Scientific Cat# P3566
Annexin V ThermoFisher Scientific Cat# A13201
Critical Commercial Assays
Mouse VEGF ELISA Peprotech Cat# 900-K99
Mouse VEGF Quantikine ELISA kit R&D Systems Cat# MMV00
Human VEGF Quantikine ELISA kit R&D Systems Cat# DVE00
Experimental Models: Cell Lines
Primary mouse endothelial cells prepared
from C57BL/6, CGL KO, GCN2 KO and SIRT1
inducible KO mice (freshly isolated in the lab of
Dr. James Mitchell or Dr. David Sinclair for
each experiment)
Jackson Laboratories and laboratory
of Dr. James R. Mitchell
Cat# 000664; this paper; Das et al., 2018
Primary mouse myotubes from GCN2 WT and
KO mice
From the laboratory of
Dr. James R. Mitchell
This paper
Primary CGL WT and KO mouse tail dermal
fibroblasts
From the laboratory of
Dr. James R. Mitchell
This paper
Primary mouse hepatocytes from WT mice From the laboratory of
Dr. James R. Mitchell
This paper
Immortalized MEFs From the laboratory of
Dr. James R. Mitchell
This paper
HUVECs Lonza Cat# CC-2519
C2C12 ATCC Cat# CRL-1772
Experimental Models: Organisms/Strains
C57BL/6 male and female Mice Jackson Laboratories Cat# 000664
WT and KO CGL male and female mice on
mixed 129/C57BL/6 background
Strain originally from Dr. Rui Wang
and bred in the lab of
Dr. James R. Mitchell
Yang et al., 2008; Hine et al., 2015
GCN2 WT and KO male and female mice Strain originally from Dr. David Ron
and bred in the lab of
Dr. James R. Mitchell
Peng et al., 2012
Oligonucleotides
si-Scramble (Selective negative control
No.1 siRNA)
ThermoFisher Scientific Cat# 4390843
Mouse si-PGC1a (PPARGC1A) ThermoFisher Scientific Cat# n253420
(Continued on next page)
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Mouse si-HIF1a ThermoFisher Scientific Cat# s67530
Human si-ATF4 ThermoFisher Scientific Cat# s1704
Human si-PGC1alpha (PPARGC1A) ThermoFisher Scientific Cat# s21394
Human si-HIF1a (HIFA) ThermoFisher Scientific Cat# s6539
Human si-eNOS (NOS3) ThermoFisher Scientific Cat# s9623
human ACTIN/ACTB F: GTTGTCGACGAC
GAGCG R: GCACAGAGCCTCGCCTT
N/A N/A
human ASNS F: GCGGAGTGCTTCAATGT
AAC R: CCAATAAGAAAGTGTTCCTGGG
N/A N/A
human ATF4 F: CTATACCCAACAGGGCA
TCC R: GTCCCTCCAACAACAGCAAG
N/A N/A
For a full list of all primers used, please
see Table S1
N/A N/A
Recombinant DNA
prK-ATF4 overexpression plasmid Addgene 26114
Software and Algorithms
ImageJ National Institutes of Health https://imagej.nih.gov/ij/download.html
GraphPad Prism GraphPad Version 7.0
FlowJo FlowJo https://www.flowjo.com/solutions/flowjo
Fiji software GPL v2, Fiji http://fiji.sc/Fiji
MATLAB R2017A MathWorks https://www.mathworks.com/programs/
trials/trial_request.html?prodcode=MLCONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, James R.
Mitchell (jmitchel@hsph.harvard.edu)
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Mice
All experiments were performedwith the approval of the HarvardMedical Area or Boston University Institutional Animal Care andUse
Committee (IACUC). 8-14 week old male or female C57BL/6 mice (The Jackson Laboratory, Bar Harbor, ME) were used for all ex-
periments unless otherwise indicated. Male and female CGL WT and KO mice on a mixed 129/C57BL/6 background (Yang et al.,
2008) and GCN2KO and control mice on a C57BL/6 background (Peng et al., 2012) were bred at our facility. Except where indicated,
animals were maintained under standard group housing conditions with ad libitum (AL) access to food (Purina 5058) and water, 12-hr
light/12-hr dark cycles, temperature between 20–23C with 30%–70% relative humidity.
Experimental diets were based on Research Diets D12450Bwith approximately 18%of calories from protein (hydrolyzed casein or
individual crystalline amino acids (Ajinomoto) in the proportions present in casein), 10% from fat and 72% from carbohydrate. MR
diets containing 1.5g methionine (M)/kg food and lacking cysteine (C) (Miller et al., 2005) in the context of a 14% protein/ 76% car-
bohydrate calorie diet were provided AL. In MR experiments with WT and CGLKO mice, the control diet was supplemented with
4.3g C/kg food to compensate for the inability of CGLKO mice to make C. AL food intake/g body weight was monitored daily for
several days and used to calculate calorie restriction (CR) based on initial animal weights. Animals were fed daily with fresh food
between 6-7 PM.
Where indicated, axitinib was supplemented at a daily dose of 30 mg/kg/d in the food as previously described (Alonso et al.,
2010; Ma and Waxman, 2008); and PAG was dosed once daily i.p. (10 mg/kg) for the indicated time.
Cell Lines and Primary Tissue Culture Studies
Pooled human umbilical vein endothelial cells (HUVECs) were obtained from Lonza (C2519A, Lonza) and used between passage
1 and 7. HUVECs were cultured in endothelial basal medium (EBM-2) supplemented with 2% FBS and endothelial growth medium
SingleQuots (Clonetics, Lonza) at 37C in a humidified, multigas incubator (Napco Series 8000WJ, Thermo Scientific) at 5%CO2 and
3% O2 achieved by displacing air with nitrogen gas.e3 Cell 173, 117–129.e1–e8, March 22, 2018
Primary mouse endothelial cells were isolated from the lung by collagenase digestion (Liberase, Roche) followed by sequential af-
finity selection using Dynabeads goat anti-rat conjugated to rat-anti mouse CD31 (BD Biosciences, San Jose, CA), and cultured in
endothelial basal medium (EBM-2) supplemented with 2% FBS and endothelial growth medium SingleQuots (Clonetics, Lonza) at
37C, 5% CO2 and 3% O2. At least 3 independent primary mouse EC cultures/genotype was tested per experiment.
Primarymouse hepatocyteswere isolated by collagenase digestion, Percoll (GEHealthcare) gradient centrifugation and cultured in
William’s E media (Sigma) with 5% FBS at 37C, 5% CO2 and 3% O2.
Primary mouse dermal fibroblasts (MDFs) were obtained from tail skin of WT mice following collagenase digestion and cultured in
DMEM with 10% FBS at 37C, 5% CO2 and 3% O2.
Primary mouse skeletal myotubes were isolated from leg skeletal muscle following collagenase/dispase digestion and cultured
in Ham’s F12 with 20% FBS and 10 ng/mL bFGF for approximately one week, then switched to Ham’s F12 supplemented with
4% horse serum but lacking bFGF for 7 days at 37C in 5% CO2 at normoxia (20% O2).
C2C12 myoblasts were cultured in DMEM with 10% FBS until they reached 90% confluence, then switched to DMEM supple-
mented with 4% horse serum for 7 d at 37C in 5% CO2 at normoxia (20% O2).
Immortalizedmouse embryonic fibroblasts (MEFs) were cultured in DMEMwith 10%FBS at 37C in 5%CO2 at normoxia (20%O2).
The following methionine and cysteine deprivation conditions (-M&C) were used to simulate methionine restriction in vitro. For pri-
mary EC, when cultures reached confluence, the media was removed and replaced either with complete DMEM ±M&C plus Gluta-
max (no pyruvate) (Sigma) supplemented with the same amount (2%) of dialyzed FBS and endothelial growth medium SingleQuots
(Clonetics, Lonza) for 1 to 24 hr. For hepatocytes, MDFs, primary or C2C12myotubes andMEF cultures, themedia was removed and
replaced with complete DMEM ±M&C (plus Glutamax, no pyruvate; Sigma) supplemented with dialyzed FBS (10% for hepatocytes,
MDFs and MEFs; 4% for primary skeletal muscle and C2C12 myotubes)
Where indicated, media was supplemented with L-NAME (100 mM), NaHS (100 mM), PAG (100 mM), SU5416 (20 mM), axitinib
(10 mM), Ex527 (10 mM), 2-DG (1 mM or 50 mM), Compound C (10 mM) or STO-609 (5 mg/mL). Hypoxia was induced via air displace-
ment with nitrogen gas.
METHOD DETAILS
Intramuscular adenoviral-mediated gene delivery
Local overexpression of CGL or VEGF in gastrocnemius was accomplished by intramuscular injection of 40 mL containing a total of
109 PFU of an adenovirus-type 5 (dE1/E3) containing the CMV promoter driving expression of the mouse CGL gene (Ad-mCTH/CGL,
GenBank RefSeq BC019483, ADV-256305 Vector Biolabs) or the human VEGF gene (Ad-hVEGFA165 GenBank RefSeq
NM_001171626, Vector Biolabs) or the negative control virus Ad-CMV Null (1300 Vector Biolabs) once weekly for 2 weeks.
Hindlimb ischemia model
12 week old C57BL/6 WT mice were anaesthetized with isoflurane and body temperature maintained on a circulating heated water
pad. Following a 1 cm groin incision, the neurovascular pedicle was visualized under a microscope (LW Scientific, Z2 Zoom Stereo-
scope) and the femoral nerve carefully dissected out. The femoral vein (located medially) was separated from the femoral artery
(located laterally) allowing electrocoagulation of the left common femoral artery, proximal to the bifurcation of superficial and
deep femoral artery while sparing the vein and nerve. Once the artery was occluded, the surgical site was inspected for any residual
bleeding (Hoefer et al., 2004; Mirabella et al., 2011).
Laser Doppler perfusion imaging
Laser Doppler perfusion imaging (LDPI) was performed as described previously (Hoefer et al., 2004; Mirabella et al., 2011). Briefly,
micewere kept under isoflurane anesthesia, andbody temperaturemaintained on a circulating heatedwater pad. Blood flow recovery
wasmonitored at d0 (immediately post-surgery), d1, d3, and d10 using an LDPI analyzer (Moor Instruments, DE). The LDPI intensity of
the ischemic foot was normalized to the contralateral foot and represented as relative blood flow of the ischemic limb (Ischemic/Non-
ischemic ratio). AUCs from I/NI ratios from each animal over time were used for statistical comparisons between groups.
Treadmill exercise training
12 wk old male WT and CGLKO mice were randomized into sedentary or exercise groups. Mice were acclimatized to the treadmill
(Columbus Instruments 6 lane treadmill) at 8 m/min for 5 min for 3 d prior to exercise training. Mice ran 30 min/d at 5 incline at
12 m/min for the first wk of training. Mice continued running 30 min/d at 5 incline at 14 m/min for an additional 3 wk to reach 1
mo total of exercise training. Sedentary controls and exercised animals were co-housed. Mice were euthanized 1 hr after the final
exercise bout (Narkar et al., 2008).
Treadmill exercise test
2 and 3 days after ischemic injury, mice were acclimatized to the treadmill (Columbus Instruments 6 lane treadmill) at 8 m/min for
5 min prior to exercise testing. At d4, mice were run until exhaustion at 5 incline, 8 m/min for 10 min then 10 m/min for 5 min,
with a 2 m/min increase in speed every 5 min (Narkar et al., 2008).Cell 173, 117–129.e1–e8, March 22, 2018 e4
Gene expression analysis by qPCR
Total RNA was isolated from tissues and cells using RNeasy Mini Kit (QIAGEN) and cDNA synthesized by random hexamer priming
with the Verso cDNA kit (Thermo). qRT-PCR was performed with SYBR green dye (Lonza) and TaqPro DNA polymerase (Denville).
Fold changes were calculated by theDDCt method (Livak and Schmittgen, 2001) using Hprt, 18S and/or b-Actin genes as standards,
and normalized to the experimental control. Human primer sequences are indicated in the Key Resources Table, and mouse primer
sequences are additionally found in Table S1.
Immunoblotting
Cells were homogenized with passive lysis buffer (Promega), normalized for protein content, boiled with SDS loading buffer and
separated by SDS-PAGE. Proteins were transferred to PVDF membrane (Whatman) and blotted for CGL (ab151769 Abcam),
HIF1a (10006421 Cayman Chemical), p-eIF2a Ser51 (9712S Cell Signaling), total eIF2a (9722S Cell Signaling), ATF4 (11815 Cell
Signaling), Actin (13E5 Cell Signaling) and Tubulin (2146S Cell Signaling) and secondarily with HRP-conjugated anti-rabbit antibody
(Dako).
VEGF ELISAs
Mouse and human VEGF ELISA kits were purchased from Peprotech (900-K99) and R&D System (DEV00), respectively, and assays
performed according tomanufacturer’s instructions on 100 mL of plasma or cell culture media per analysis. For analysis of VEGF pro-
tein in muscle, approximately 100 mg of frozen gastrocnemius muscle was pulverized using a mortar and pestle, and the powder
transferred to a 1.5 mL microcentrifuge tube containing 150 mL of PBS. The tissue was further disrupted using a mechanical tissue
homogenizer (Kimble Kontes Pellet Pestle, Fisher Scientific). After three cycles of freezing and thawing, the tissue suspension was
microcentrifuged at max speed for 10min and the supernatant recovered and stored at80C. Lysates were adjusted to 0.5 mg/mL in
PBS and assayed using a mouse VEGF ELISA kit from R&D systems (MMV00).
Immunohistochemistry and capillary density analysis
IHC was performed on frozen sections of unfixed gastrocnemius muscle (50 mm for CD31 quantification; 20 mm for CD31/VEGF/IB4
co-staining). After 5 min fixation in PFA 4% and rinsing in PBS, immunostaining was performed as previously described (Longchamp
et al., 2014). Primary antibodies included anti-mouse CD31 (BD Bioscience), anti-mouse VEGF (Novus Biologicals) and Isolectin B4
(Life Technologies) at a dilution of 1:100. For capillary density measurements, CD31 area was quantified from randomly photo-
graphed 10 mm stack sections (6 images per section, 4 sections per muscle per mouse) using Fiji software (http://fiji.sc/Fiji). All quan-
tifications were performed blindly.
CD31 FACS analysis
Following enzymatic digestion of muscle with collagenase/dispase mix, cells were blocked with mouse FcR blocking reagent
(Miltenyl Biotech) and stained for 30 min at 4oC in the dark with CD31APC at 1:100 (BioLegend). Cells were washed and acquired
immediately on an LSR II flow cytometer (BD Biosciences) and analyzed with FlowJo. CD31 positive endothelial cells are expressed
as a percentage of total cells recovered from the enzymatically digested muscle cells as assessed by forward and side scatter.
H2S measurements
Detection of H2S production capacity in live cultures by lead sulfide method
For detection of H2S production in live cells, growth media was supplemented with 10 mM L-cysteine and 10 mM pyridoxal 5
0-phos-
phate hydrate (PLP, Sigma), and a 6x4 inch piece of lead acetate paper, made by soaking 703 size blotting paper (VWR) in 20 mM
lead acetate (Sigma) and then vacuum dried, was placed over the plate for 2-24 hr of further incubation in a CO2 incubator at 37
C
until lead sulfide was detected but not saturated.
Detection of endogenous H2S with fluorescent P3 probe in cultured cells or frozen tissue sections
For detection of endogenous H2S production in live adherent cells, growth media was supplemented with 10 mM P3 probe (Singha
et al., 2015) for 30min prior to fixation. Quantification was performed by calculating the average P3 signal intensity per cell. Cell areas
were automatically segmented using brightfield images. Values presented are average P3 intensity per cell, corrected for total cell
area. Analyses were performed using MATLAB R2017A.
For detection of endogenous H2S production in tissue sections, 50 mm frozen sections of unfixed gastrocnemiusmuscle were incu-
bated with 20 mMP3 probe for 5 min and washed 2X with PBS. Sections were then fixed for 5 min in 4% PFA prior to immunostaining
using a 2 photon microscope (Zeiss LSM780 w/ Mai Tai HP 2-photon laser (Spectra Physics) at 880 nm excitation and 520-550 nm
emission (Singha et al., 2015).
Genetic manipulations in cultured cells
siRNA knockdown
siRNA knockdown of human activating transcription factor 4 (ATF4), human endothelial nitric oxide synthase (eNOS), human hyp-
oxia-inducible factor 1a (HIF1a), PGC1a (PPARGC1A) in HUVECs as well as mouse HIF1a and PGC1a in C2C12 myoblasts was per-
formed using lipofectamine RNAiMAX (Life Technologies) and 30 nM siRNA purchased from Ambion (Ambion, ThermoFisher) ase5 Cell 173, 117–129.e1–e8, March 22, 2018
described previously (Hine et al., 2015). All experiments were performed 2 days after transfection. Knockdown was confirmed by
immunoblot and/or qPCR.
shRNA knockdown of ATF4
MDFs were infected overnight in complete medium and collected 2 days later using Ad-m-ATF4-shRNA or the negative control virus
Ad-CMV Null adenovirus amplified and purified by Vector Biolabs (Philadelphia, PA, U.S.A.).
ATF4 overexpression
ATF4 overexpression in HUVECswas performed using Lipofectamine 2000 (Life Technologies) and 1 mg of prK-ATF4 plasmid per well
(12-well format) overnight. All experiments were performed 2 days after transfection. Overexpression was confirmed by immunoblot
and/or qPCR.
Adenoviral-mediated CGL overexpression
HUVECs were infected overnight in complete medium using Ad-m-CTH or the negative control virus Ad-CMV Null adenovirus ampli-
fied and purified by Vector Biolabs (Philadelphia, PA, U.S.A.) and collected 2 days later.
Angiogenesis assays in vitro
Migration assay
ECs were seeded at 100,000 cells per well in a 24-well plate in EGM with 2% serum and growth factors (Lonza). 12 hr later, media
was switched to EGM without serum/growth factors, and in some cases mitotically arrested (1 mg/mL MitoC). A single scratch was
created using a sterile p200 pipette tip on a confluent field of EC. Floating cells were washed away and EGM (or DMEM ±M&Cmedia)
with dialyzed serum and growth factors replaced, including treatments. Repopulation/migration across the scratch was recorded by
phase-contrast microscopy every 4 hr for up to 20 hr using a digital camera. Migration across the scratch (gap area at t = X hr relative
to t = 0 hr) was determined at each time point from digital images using ImageJ software.
Tube formation
Formation of tube networks was assessed as described previously (Borradaile and Pickering, 2009). HUVECs were seeded at 10,000
cells per well in a 24-well plate (Corning) coated with 150 mL Cultrex reduced growth factor basement membrane extract (Trevigen).
Following an 18 hr-incubation, resulting tube networks were analyzed by light microscopy (Nikon Eclipse TiE). The total length of
tubule networks and the number of branch points were quantified by ImageJ software.
Spheroid capillary sprouting assay
Hanging drops of HUVECs or primarymouse ECs in EGM2 (De Bock et al., 2013) were embedded inMatrigel (Corning) and cultured
in the indicated media for 24 hr to induce sprouting. Compounds were added at the indicated concentrations during the gel culture
step, using corresponding vehicle concentrations as control. Spheroid cultures were stained with phalloidin diluted 1:500 in PBST
for 1 hr at RT and counterstained with DAPI. Images were captured with a Zeiss LSM 510 Meta NLO confocal microscope (oil ob-
jectives: x 40 with NA 1.3, x 63 with NA1.4, x 100 with NA 1.3; Carl Zeiss, Munich, Germany) or a Leica laser-scanning SP5 confocal
microscope (Leica, Manheim, Germany). Analysis of the sprout length was performed using ImageJ software.
Proliferation
HUVECs were cultured to 60% confluency in a 12-well plate on glass coverslips, washed with PBS and incubated for 24 hr in EGM2
containing 0.1 mM BrdU. Immunostaining was performed on cells washed and fixed for 5 min in 20C acetone, air-dried, rinsed in
PBS and permeabilized for 1 hr in PBS supplemented with 2% BSA and 0.1% Triton X-100. BrdU positive nuclei were automatically
detected using the ImageJ software and normalized to the total number of DAPI-positive nuclei.
Glucose uptake
For VEGF and NaHS treatment ± Compound C (10 mM) (Figures 5D and S6A), HUVECs were pretreated for 1 hr with 50 ng/ml VEGF
(Peprotech) or 100 mMNaHS. Cells were then depleted in Krebs-Ringer Bicarbonate Buffer (KRB; NaH2PO4/Na2HPO4 10 mM, NaCl
136mM, KCl 4.7mM,MgSO4 1.25mM, CaCl2 1.25mM, pH7.4), without glucose and serum for 30min and then incubated for 6min in
a solution containing 0.5 mCi 3H-2-DG. On ice, cells were then washed in cold PBS 3 times, lysed, and sample counted in a liquid
scintillation counter. Samples were normalized to protein content as measured from the same cells by BCA. For remaining glucose
uptake experiments (Figures S5B, S6G, S6I and 6G), EC were treated with NaHS (100 mM), KCN (10 mM), Antimycin A (2.5 mM), Oli-
gomycin (2 mM), or FCCP (1.5 mM) for 45, 75 or 195min in EGM-2.When indicated, inhibitors were added 30min before the addition of
the tracer. Fifteen min before the termination of the experiment, 0.4 mCi of 3H-2-DG was added to each well (1 mL final volume,
12-well format). At the end of the incubation the plate was rapidly transferred on ice, media removed and washed 4 times with
PBS + BSA 0.1%. Finally, cell lysis was performed with NaOH 0.2% + SDS 0.5%. Lysate (500 mL) was mixed with scintillation fluid
(5 mL) and sample radioactivity measured in a scintillation counter (Beckman).
Glycolytic flux analysis
HUVECs were cultured with standard media (EGM-2), and stimulated for up to 3 hr with test compounds (NaHS 100 mM, VEGF
50ng/mL, Antimycin A 2.5 mM, Oligomycin 2 mM, or 2-DG 1mM). 15 min before the end of the incubation, 5 mCi D-[5-3H(N)]-glucose
was added to 1.5 mL media (12-well format), then the plate was rapidly transferred on ice, and the media (1.5 mL) transferred into a
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with 3 mL water. The tube was tightly capped and evaporation was performed at room temperature for 48 hr. Finally, 2 mL of water
was collected from the 50mL tube and mixed with 10 mL of scintillation fluid. Sample radioactivity was measured in a scintillation
counter (Beckman).
ATP and ATP/ADP ratio
Cells in a 96-well format were treated with NaHS, VEGF or 2-DG in a reverse time course. ATP was measured by addition of 70 mL of
Cell TITER-Glo (Promega), plate incubated in the dark for 10min and luminescence quantified by a plate reader (BioTek instruments).
ADP/ATP ratio was calculated after measuring ADP and ATP by a commercially available enzymatic assay (ApoSENSOR, BioVision),
according to the manufacturer’s instructions.
Energy charge
Steady-state mass spec measurements of AMP, ADP and ATP were used to calculate energy charge using the following equation:
(ATP +1/2ADP)/(ATP + ADP + AMP).
Lactate
Lactate in HUVEC culture media was measured after 1.5-6 hr of treatment with NaHS (100 mM). The assay was performed using a
plate-based colorimetric assay (Cell Biolabs) according to the manufacturer’s protocol.
Cell death and ROS
Apoptosis and cell death were measured after 12 hr treatment with NaHS (100 mM) or –M&C using a FACS-based annexin V/propi-
dium iodide assay according to the manufacturer’s protocol (BD Biosciences).
Reactive oxygen species were measured after 15 min, 1 hr and 2 hr incubations with NaHS (100 mM), FCCP (2 mM) or KCN (10 mM).
Menadione (10 mM)was used as a positive control. Cells were stained for 15minwith CellROXGreen dye in the treatmentmedia, fixed
with 2% paraformaldehyde and measured using FACS.
Seahorse
Cellular oxygen consumption and extracellular acidification rate was measured using the Seahorse Cell Metabolism Analyzer XF96
(Seahorse Biosciences). Cells were plated at a density of 12,000 cells and untreated or pretreated with 100 mMNaHS, 10 mMKCN or
500 mM phenformin for 2 hr. After 2 hr, media was changed to unbuffered XF assay media with 0 or 11 mM glucose, 0 or 2 mM gluta-
mine and pyruvate at pH7.4 and basal OCR and ECARmeasured for 5 blocks of 2 min mixing and 5 min measuring. Glucose (10 mM
final), 2-DG (50 mM final) and Oligomycin (2.5 mM final) were injected at indicated times. All plates were normalized to protein content
as measured from the same cells after Seahorse by BCA.
Mitochondrial respiration in permeabilized cells using complex-specific substrates was measured in a Seahorse Cell Metabolism
Analyzer XF24 (Seahorse Biosciences) as previously described (Salabei et al., 2014). Briefly, cells were plated at a density of 100,000
cells in EGM-2. Four hr later, cells were pretreated with 100 mMNaHS or 10 mMKCN for 1 hr, then washed with MAS buffer and incu-
bated with MAS buffer containing 10 mM pryruvate, 2 mM malate, 4 mM FCCP and 25 mg/mL Saponin for 1 hr. OCR was measured
for 10 blocks of 1 min mixing and 2 min measuring. Rotenone (1 mM final), Succinate (10 mM final), Antimycin A (20 mM final), and
TMPD/Ascorbate (0.5 mM/2 mM final) were injected in order.
Metabolite profiling for glucose flux analyses
To determine the relative levels of intracellular metabolites, extracts were prepared and analyzed by LC/MS/MS. Triplicate 15-cm
confluent plates were incubated in EGM-2 media in presence or absence of 100 mM NaHS 105 min prior to extraction. For
D-[1,2-13C ]- glucose flux studies, cells were washed once with serum- and glucose free DMEM and then incubated in DMEM
containing a 10 mM 1:1 mixture of D-[1,2-13C ]-glucose and unlabeled D-glucose for 15 min. Metabolites were extracted on dry
ice with 4 mL 80% methanol (80C) as described previously (Ben-Sahra et al., 2013). Insoluble material was pelleted by centrifu-
gation at 3000g for 5 min, followed by two subsequent extractions of the insoluble pellet with 0.5 mL 80% methanol, with centrifu-
gation at 16,000g for 5 min. The 5 mL metabolite extract from the pooled supernatants was dried down under nitrogen gas using an
N-EVAP (Organomation Associates).
Dried pellets were resuspended using 20 mL HPLC grade water for mass spectrometry. 10 mL was injected and analyzed using a
5500 QTRAP triple quadrupole mass spectrometer (AB/SCIEX) coupled to a Prominence UFLC HPLC system (Shimadzu) via
selected reaction monitoring (SRM). Some metabolites were targeted in both positive and negative ion mode for a total of 287
SRM transitions using pos/neg polarity switching. ESI voltage was +4900V in positive ion mode and –4500V in negative ion
mode. The dwell time was 3 ms per SRM transition and the total cycle time was 1.55 s. Approximately 10-14 data points were
acquired per detected metabolite. Samples were delivered to the MS via normal phase chromatography using a 4.6 mm i.d. x
10 cm Amide Xbridge HILIC column (Waters) at 350 mL/min. Gradients were run starting from 85% buffer B (HPLC grade acetonitrile)
to 42% B from 0-5 min; 42% B to 0% B from 5-16 min; 0% B was held from 16-24 min; 0% B to 85% B from 24-25 min; 85% B was
held for 7 min to re-equilibrate the column. Buffer A was comprised of 20 mM ammonium hydroxide/20 mM ammonium acetate
(pH = 9.0) in 95:5 water:acetonitrile. Peak areas from the total ion current for each metabolite SRM transition were integrated usinge7 Cell 173, 117–129.e1–e8, March 22, 2018
MultiQuant v2.0 software (AB/SCIEX). For stable isotope labeling experiments, custom SRMs were created for expected 13C incor-
poration in various forms for targeted LC/MS/MS. Samples were quantile normalized and log transformed andmetabolites were par-
eto scaled prior to analysis. Analyses were performed using R version 3.3.2.
Global metabolite profiling
HUVECs grown in EBM-2 media with BulletKit were switched to DMEM with 2% dialyzed FBS and all non-serum BulletKit compo-
nents. After a 1 hr equilibration period, cells were switched to treatment media (control, -M&C, NaHS 100 mM). After the treatment
period (15 min, 2 hr, 4 hr) cells were collected and analyzed for total metabolite profile by mass spectrometry using the methods
detailed in the preceding section.
QUANTIFICATION AND STATISTICAL ANALYSIS
Data are displayed as means ± standard deviation (SD) and statistical significance assessed in GraphPad Prism using Student’s
t test, one-way or two-way ANOVA unless otherwise specified. A P value of 0.05 or less was deemed statistically significant.Cell 173, 117–129.e1–e8, March 22, 2018 e8
Supplemental Figures
Figure S1. SAA Restriction Induces Endothelial VEGF Expression In Vitro and Functional Angiogenesis In Vivo, Related to Figure 1
(A) Tube formation assay: Quantification of tube branch points per field of view in HUVECs seeded onto growth factor-replete Matrigel and incubated in the
indicated media ± SIRT1 inhibitor Ex-527 for 18 hr; n = 8-10 data points/condition.
(B) Daily body weight (left, n = 5 mice/group) and food intake expressed as grams of food eaten per gram of mouse body weight (right, n = 2 cages/group) of mice
given ad libitum access to M restricted (MR) versus control (Ctrl) diet for 2 mo in a representative experiment.
(C) Representative flow cytometric analysis of CD31 positive cells from gastrocnemius muscle of mice fed for 2 wk on Ctrl or MR diets with or without VEGFR2
inhibition (axitinib, +A) expressed as a percentage of total cells recovered from the enzymatically digested muscle tissue; quantification at right (n = 3-6
mice/group).
(D) Expression of VEGF mRNA in gastrocnemius muscle of mice subject to MR for 2-8 wk expressed relative to Ctrl diet group; n = 22-23/mice group.
(E) VEGF protein levels in extracts of muscle from mice on the indicated diet for at least 2 wk as determined by ELISA; n = 11-13/group.
(F) Representative transverse sections of gastrocnemius muscle stained for VEGF (left, 40X mag), IsolectinB4 (IB4, middle, 40X mag) and merged (VEGF red, IB4
green, DAPI blue; right, insert 160X mag) in mice preconditioned for 2 mo on control (Ctrl) or M restricted (MR) diets.
(G) Schematic representation of the hindlimb ischemia procedure.
(H and I) Longitudinal Doppler imaging of blood flow (H) and distance run on treadmill exercise test (I) following ischemia inWTmice preconditioned on a complete
diet fed ad libitum (AL) or calorie restricted daily by 40% of the AL amount (CR) for 1 mo prior to femoral artery ligation, +/propargylglycine (PAG) daily for 1 wk
prior to ligation and 2 wk after as indicated. (H) Left: representative infrared images on the indicated after ligation (I, ischemic; NI, non-ischemic). Right: quan-
tification of blood flow recovery with individual animal AUCs used for statistical comparisons; n = 6 mice/group. (I) Distance run on treadmill exercise test on d4
after ligation of the indicated groups from (H).
Error bars indicate SD; asterisks indicate the significance of the difference by Student’s t test or one-way ANOVAwith Sidak’s multiple comparisons test between
diets in vivo or sulfur amino acid levels in vitro; *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
Figure S2. GCN2-Dependent, Hypoxia-Independent Regulation of VEGF and Angiogenesis upon SAA Restriction, Related to Figure 2
(A) Immunoblot of HIF1a protein in HUVECs 2 d after transfection with HIF1a siRNA or control scrambled (Sble) siRNA.
(B) Quantification of immunoblots from Figure 2B of the indicated protein from HUVEC extracts after culturing in control (Ctrl) or M&C deficient media (M&C).
(C) PGC1a mRNA levels of HUVECs cultured in the indicated media for 16 hr; n = 4 experiments/group, error bars indicate SEM.
(D and E) PGC1a (D) and VEGF (E) mRNA levels in HUVECs 2 d after transfection with a PGC1a overexpressing construct, and expressed relative to cells
transfected with a control AdGFP vector; n = 3 experiments/group, SEM.
(F) Asns (left) and ATF4 (right) mRNA expression in HUVECs 2 d after transfection with ATF4 siRNA or control scrambled (Sble) siRNA and cultured in the indicated
media for 16 hr; n = 4 experiments/group, SEM.
(G–I) Immunoblot of ATF4 protein (G), mRNA expression of ATF4 (H) and Asns (I) in HUVECs 2 d after transfection with a CMV-driven ATF4 overexpressing
construct (ATF4OE) or empty vector (Empty).
(J) Representative images of primary WT mouse ECs stained for CD31 (red), Actin (green) and DAPI (blue) at 40X mag; n = 3 experiments/group, SEM.
(K) Asns mRNA in WT and GCN2KO primary mouse ECs from n = 5-6 mice per genotype cultured as indicated for 16 hr.
(L) VEGF mRNA in MDFs 2 d after infection with shATF4 or control scrambled adenovirus and cultured for the final 16 hr as indicated; n = 5-8
experiments/group, SEM.
(M) HIF1amRNA expression in C2C12 cells 2 d after transfection with HIF1a siRNA or control scrambled (Sble) siRNA and then cultured for an additional 16 hr in
control media; n = 11-12 experiments/group, SEM.
(N and O) C2C12 HIF1a protein level (N) and VEGF mRNA expression (O) 2 d after transfection with HIF1a siRNA or control scrambled (Sble) siRNA, and then
cultured for an additional 24 hr under 20% or < 1% oxygen tension in presence or absence of M&C; n = 3-6 experiments/group, SEM.
(P) Relative PGC1a (left) and VEGF (right) mRNA expression in HUVECs 2 d after transfection with PGC1a siRNA or control scrambled (Sble) siRNA and cultured in
the indicated media for 16 hr; n = 3 experiments/group, SEM.
Unless otherwise indicated, error bars indicate SD; asterisks indicate the significance of the difference between SAA levels or genetic interventions by Student’s
t test; or between SAA levels within genotype/intervention/condition by one-way ANOVA with Sidak’s multiple comparisons test; *p < 0.05, **p < 0.01,
***p < 0.001.
Figure S3. VEGF Signaling and AASR Converge on Endothelial H2S Production by CGL, Related to Figure 3
(A) Representative images (10Xmag) of H2S-specific probe (P3) fluorescence in primarymouse hepatocytes treatedwith VEGF (50ng/ml) or deprived of all AAs as
well as serum (-Nutrients) for 16 hr.
(B) VEGF mRNA in WT and CGLKO primary mouse ECs (n = 3 mice/group) cultured in M&C deficient media relative to control (Ctrl) media for 16 hr; error bars
indicate SD; one-way ANOVA with Sidak’s multiple comparisons test between SAA levels.
(C and D) CBS, CGL and 3-MSTmRNA expression (C) and protein level (D) in HUVEC 16 hr after treatment with VEGF; n = 3 experiments/group, error bars indicate
SEM; Student’s t test. **p < 0.01, ***p < 0.001.
Figure S4. CGL Required for Angiogenesis In Vivo, Related to Figure 4
(A) H2S production capacity of gastrocnemius muscle extracts of Ad Null or Ad-CGL infected mice 1 wk after the final intramuscular injection.
(B) Expression of VEGF mRNA in the gastrocnemius muscle of mice subjected to low-intensity exercise (Run) versus sedentary controls (Sed) for 1 mo;
n = 4 mice/group.
Error bars indicate SD; asterisks indicate the significance of the difference between exercise groups by Student’s t test; **p < 0.01.
Figure S5. H2S Promotes Glucose Uptake and ATP Generation by Glycolysis for EC Migration, Related to Figure 5
(A) HUVEC proliferation over a 24 hr period ± NaHS (100 mM) as assessed by radiolabelled thymidine incorporation; n = 5-9 experiments/group, error bars
indicate SEM.
(B) Glucose uptake in SIRT1KO primary mouse ECs treated in triplicate as indicated.
(C) Extracellular acidification rate (ECAR) in HUVECs pretreated for 2 hr with NaHS (100 mM); n = 8 technical replicates from each of 2 experiments.
(D) ECAR over time inmouse ECs pretreated for 2 hr with VEGF (50 ng/ml) or NaHS (100 mM) and then treated with 10mMGlucose, 2.5 mMOligomycin and 50mM
2-DG injection as indicated by the arrows; representative experiment shown.
(E) Fold change of lactate concentration in the media of HUVECs treated with NaHS (100 mM) for 1.5-6 hr versus control; n = 3 experiments per group; SEM.
(F) Glycolytic flux in HUVECs at the indicated time after NaHS addition; n = 3 technical replicates/time point; one-way ANOVA with Dunnett’s multiple com-
parisons test versus t = 0.
(G) Log2 fold change of unlabeled metabolites in HUVECs treated for 1 hr with NaHS (100 mM) versus control.
(H) ECAR over time in HUVECs pre-treated for 2 hr with axitinib (10 mM) or L-NAME (100 mM) and then treatedwith NaHS or 2-DG as indicated by the arrows; n = 15
technical replicates/time point.
(I) Quantification of HUVECmigration across scratch ± NaHS (100 mM) or eNOS inhibitor L-NAME (100 mM); n = 5-6 AUC values/group each from cells at different
passage numbers.
(J) Immunoblot of eNOS in HUVECs 2 d after transfection with eNOS siRNA or control scramble (Sble) siRNA.
(K) Quantification of HUVEC migration across scratch 2 d after transfection with eNOS siRNA or control scramble (Sble) siRNA ± NaHS (100 mM) as indicated;
n = 6 AUC values/group each from cells at different passage number.
(L) Gating percentages based on annexin V (Ann) and propidium iodide (PI) stains in HUVECs treated with NaHS (100 mM) or –M&C for 12 hr.
Unless otherwise indicated, error bars indicate SD and asterisks indicate the significance of the difference between SAA levels by Student’s t test or between SAA
levels within genotype/condition by one-way ANOVA with Sidak’s multiple comparisons test; *p < 0.05, **p < 0.01, ***p < 0.001.
Figure S6. H2S Shifts Oxidative/Glycolytic Balance Concomitant with Inhibition of Mitochondrial OXPHOS, Related to Figure 6
(A) Glucose uptake in HUVECs treated with NaHS for 1 hr ± 10 mM Compound C (Comp C); n = 6 experiments/group, error bars indicate SEM; one-way ANOVA
with Sidak’s multiple comparisons test between ± NaHS within Comp C treatment group.
(B) Migration across scratch in HUVECs treatedwith NaHS ±CompC; n = 6 AUC values/group each from cells at different passage number; one-way ANOVAwith
Sidak’s multiple comparisons test between ± NaHS within Comp C treatment group.
(C and D) Schematic of the experiment (C) and quantification of migration across scratch (D) in HUVECs treated with NaHS for 10min in the presence of vehicle or
CompC; n = 5-6 AUC values/group each from cells at different passage number; one-way ANOVAwith Sidak’s multiple comparisons test between ±NaHSwithin
Comp C treatment group.
(E) ATP/ATP ratio over time in HUVECs treated with the indicated compounds; representative of 2 experiements; n = 4-12 values/time point.
(F) Energy charge calculated from ATP, ADP and AMP measurements by mass spec in HUVECs treated for 15 min with NaHS; n = 6 values pooled fro 2 in-
dependent experiments; Student’s t test.
(G) Glucose uptake in HUVECs treated with NaHS or the CamKKb inhibitor STO-609; n = 3-9 values pooled from 2 independent experiments; one-way ANOVA
with Sidak’s multiple comparisons test between control and NaHS within STO or vehicle treatement group.
(H) ROS levels expressed as mean fluorescent intensity (MFI) in HUVECs treated over time with NaHS (100 mM), KCN (10 mM), FCCP (2 mM) or menadione
(MD, 10 mM) as indicated; n = 2 values/time point.
(I) Time dependent glucose uptake in HUVEC treated with NaHS, KCN or antimycin as indicated; each time point is in triplicate.
(J) Extracellular acidification rate (ECAR) over time in HUVECs pretreated for 2 hr with 10 mMcyanide (KCN), 2 mMoligomycin (Oligo) or 500 mMphenformin (Phen)
and then treated with 10 mM glucose, 2.5 mM oligomycin and 50 mM 2-DG as indicated by the arrows; n = 20 technical replicates pooled from 2 independent
experiments.
(K) Glycolytic flux in HUVECS pretreated for 1-3 hr with oligomycin, antimycin A or 2-DG as indicated; n = 2-6 experiments/group; one-way ANOVAwith Dunnett’s
multiple comparisons test relative to control.
(L) Representative images of migration across a scratch (10Xmag at t = 20 hr; dotted lines indicate boundary of the scratch at t = 0 hr) fromHUVECs cultured in the
presence of 10 mM KCN (left), 500 mM phenformin (Phen, middle) or 2 mM oligomycin (Oligo, right) +/1 mM 2-DG as indicated.
Unless otherwise noted, error bars indicate SD; *p < 0.05, **p < 0.01, ***p < 0.001.
